TY - JOUR
T1 - BCR-ABL PCR testing in chronic myelogenous leukemia
T2 - Molecular diagnosis for targeted cancer therapy and monitoring
AU - Luu, Martin H.
AU - Press, Richard D.
PY - 2013
Y1 - 2013
N2 - The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.
AB - The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.
KW - RQ-PCR
UR - http://www.scopus.com/inward/record.url?scp=84885606228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885606228&partnerID=8YFLogxK
U2 - 10.1586/14737159.2013.835573
DO - 10.1586/14737159.2013.835573
M3 - Review article
C2 - 24063401
AN - SCOPUS:84885606228
SN - 1473-7159
VL - 13
SP - 749
EP - 762
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 7
ER -